Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the protein: clinical, genetic and biochemical characterisation by Liu, Y-T et al.
 Liu, Y-T, Hersheson, J, Plagnol, V, Fawcett, K, Duberley, KEC, Preza, E, 
Hargreaves, IP, Chalasani, A, Laura, M, Wood, NW, Reilly, MM and Houlden, H
 Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation 
that elongates the protein: clinical, genetic and biochemical characterisation
http://researchonline.ljmu.ac.uk/id/eprint/13692/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Liu, Y-T, Hersheson, J, Plagnol, V, Fawcett, K, Duberley, KEC, Preza, E, 
Hargreaves, IP, Chalasani, A, Laura, M, Wood, NW, Reilly, MM and Houlden, 
H (2013) Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 
mutation that elongates the protein: clinical, genetic and biochemical 
LJMU Research Online
RESEARCH PAPER
Autosomal-recessive cerebellar ataxia caused by a
novel ADCK3 mutation that elongates the protein:
clinical, genetic and biochemical characterisation
Yo-Tsen Liu,1,2,3,4 Joshua Hersheson,2 Vincent Plagnol,5 Katherine Fawcett,2
Kate E C Duberley,2 Elisavet Preza,2 Iain P Hargreaves,6 Annapurna Chalasani,6
Matilde Laurá,1,2 Nick W Wood,2 Mary M Reilly,1,2 Henry Houlden1,2
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
jnnp-2013-306483).
1MRC Centre for
Neuromuscular Diseases,
UCL Institute of Neurology
and National Hospital for
Neurology and Neurosurgery,
London, UK
2Department of Molecular
Neuroscience, UCL Institute of
Neurology and National
Hospital for Neurology and
Neurosurgery, London, UK
3Section of Epilepsy,
Department of Neurology,
Neurological Institute, Taipei
Veterans General Hospital,
Taipei, Taiwan
4National Yang-Ming University
School of Medicine, Taipei,
Taiwan
5University College London,
Genetics Institute, London, UK
6Neurometabolic Unit, National
Hospital of Neurology and
Neurosurgery, London, UK
Correspondence to
Professor Henry Houlden,
Department of Molecular
Neuroscience and MRC Centre
for Neuromuscular Diseases,
UCL Institute of Neurology and
National Hospital for
Neurology and Neurosurgery,
Queen Square House, Queen
Square, London WC1N 3BG,
UK; h.houlden@ucl.ac.uk
Received 8 August 2013
Revised 7 October 2013
Accepted 14 October 2013
Published Online First
11 November 2013
To cite: Liu Y-T,
Hersheson J, Plagnol V,
et al. J Neurol Neurosurg
Psychiatry 2014;85:
493–498.
ABSTRACT
Background The autosomal-recessive cerebellar ataxias
(ARCA) are a clinically and genetically heterogeneous
group of neurodegenerative disorders. The large number
of ARCA genes leads to delay and difficulties obtaining
an exact diagnosis in many patients and families.
Ubiquinone (CoQ10) deficiency is one of the potentially
treatable causes of ARCAs as some patients respond to
CoQ10 supplementation. The AarF domain containing
kinase 3 gene (ADCK3) is one of several genes
associated with CoQ10 deficiency. ADCK3 encodes a
mitochondrial protein which functions as an electron-
transfer membrane protein complex in the mitochondrial
respiratory chain (MRC).
Methods We report two siblings from a consanguineous
Pakistani family who presented with cerebellar ataxia and
severe myoclonus from adolescence. Whole exome
sequencing and biochemical assessment of fibroblasts
were performed in the index patient.
Results A novel homozygous frameshift mutation in
ADCK3 ( p.Ser616Leufs*114), was identified in both
siblings. This frameshift mutation results in the loss of
the stop codon, extending the coding protein by 81
amino acids. Significant CoQ10 deficiency and reduced
MRC enzyme activities in the index patient's fibroblasts
suggested that the mutant protein may reduce the
efficiency of mitochondrial electron transfer. CoQ10
supplementation was initiated following these genetic
and biochemical analyses. She gained substantial
improvement in myoclonic movements, ataxic gait and
dysarthric speech after treatment.
Conclusion This study highlights the importance of
diagnosing ADCK3 mutations and the potential benefit
of treatment for patients. The identification of this new
mutation broadens the phenotypic spectrum associated
with ADCK3 mutations and provides further
understanding of their pathogenic mechanism.
INTRODUCTION
Autosomal-recessive cerebellar ataxias (ARCA) are
a group of inherited neurodegenerative disorders
characterised primarily by cerebellar ataxia, but are
frequently associated with other neurological mani-
festations including spasticity, peripheral neur-
opathy, seizures and optic atrophy. ARCAs are
genetically heterogeneous with more than 20 causa-
tive genes currently recognised.1–3 Coenzyme Q10
(CoQ10) deficiency (MIM_607426) is one of the
potentially treatable causes of ARCA as the symp-
toms in many patients improve with CoQ10 sup-
plementation.4 5 CoQ10 is a lipid-soluble
component located in the inner mitochondrial
membrane. It plays a pivotal role in the oxidative
phosphorylation system (OXPHOS) by shuttling
electrons derived from mitochondrial respiratory
chain (MRC) complexes I (NADH ubiquinone
oxidoreductase) and II (succinate ubiquinone oxi-
doreductase) to complex III (ubiquinol cytochrome
c oxidoreductase), and also participates in other
cellular processes as a potent antioxidant, and by
influencing pyrimidine metabolism.6 7
The AarF domain containing kinase 3 gene
(ADCK3, MIM_606980) is one of the genes
involved in the biosynthetic pathway of CoQ10,
thus, their mutations can cause CoQ10 deficiency
where most mutations are at loss of function.
ADCK3 is the homologue of the yeast Coq8 gene
and encodes a mitochondrial protein which func-
tions in an electron-transferring membrane protein
complex in the MRC.8 Patients with ADCK3 muta-
tions usually have disease onset in infancy or early
childhood and can present with pure cerebellar
ataxia or a complex phenotype with additional fea-
tures, such as seizures, cognitive impairment,
depression, peripheral neuropathy, strabismus or
exercise intolerance.8–11
In this study, we report two affected siblings in
their 20 s, from a consanguineous family of
Pakistani origin, who both presented with cerebel-
lar ataxia, myoclonus and dysarthria. Whole exome
sequencing (WES) performed in the index patient
identified a homozygous frameshift mutation in
ADCK3. This mutation results in the loss of the
stop codon and extension of the protein by 81
amino acids. CoQ10 level and the MRC enzyme
activities in the index patient’s fibroblasts were also
investigated and CoQ10 supplementation was given
to her based on the genetic and functional results.
Significant improvements in all symptoms men-
tioned above were observed after treatment.
PATIENTS AND METHODS
Patients
With informed consent, we clinically evaluated and
obtained blood samples from the index patient and
the affected sibling. A skin biopsy was also obtained
from the index patient. This study was approved by
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the joint ethics committee of UCL Institute of Neurology and The
National Hospital for Neurology and Neurosurgery, London, UK.
WES and variant calling
In an attempt to rapidly identify the underlying genetic muta-
tion, WES was carried out on the index patient at the NIH
(Bethesda, USA). Nimblegen SeqCap EZ Exome kit (in solution
capture) was used for the exome capture. Shotgun sequencing
libraries were generated from 3 mg genomic DNA which was
extracted from peripheral blood using Flexigene extraction kit
and Autopure LS (Qiagen) extraction system. Sequencing was
performed on a Genome Analyzer IIx, according to the manu-
facturer’’s instruction. FASTQ files were aligned to the hg19 ref-
erence sequence using Novoalign V.2.07.19, including hard and
soft clipping, quality calibration and adapter trimming.
Duplicate reads were excluded using the PICARD tool
MarkDuplicates. Calling was performed using SAMtools V.0.18
and single sample calling. The resulting calls were annotated
with ANNOVAR. Candidate variants were filtered based on
function: frameshift, premature stop, non-synonymous or
potential splice-altering variants (defined as being within 5 bp of
the actual splice site) and frequency (<0.5% in the 1000
Genomes and the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project database (http://evs.gs.
washington.edu/EVS/) for homozygous and compound hetero-
zygous variants, and absent from both of these databases for
heterozygous variants). VCF tools were used to annotate gene
information for the remaining novel variants. The Integrative
Genomics Viewer (IGV) was used to inspect variants.
Sanger sequencing
Genomic DNAs of the index patient and the affected sibling
were extracted and used in the following genetic analysis (DNAs
of the parents were unavailable). PCR of exon 15 and the adja-
cent intronic junctions of the ADCK3 gene (NM_020247)
were performed to validate the identified variant (primers
and conditions available on request). PCR products were purified
on Montage PCR 96 Cleanup Plates (Millipore, Bedford,
Massachusetts, USA) and used in sequencing reactions with the
ABI BigDye Terminator V.3.1 Cycle Sequencing Kit (Applied
Biosystems), and subsequently cleaned using BigDye Terminator
removal plates (Applied Biosystems). PCR products were resolved
on Applied Biosystems 3730XI Sequencer. Computational ana-
lyses of mutations were carried out with Sequencher software
(Gene Codes Corporation).
Cell culture
Primary fibroblasts were obtained from a skin biopsy from the
index patient. Fibroblast lines from matched healthy controls
were kindly provided by Dr Jan-Willem Taanman, UCL Institute
of Neurology and the MRC CNMD Biobank, London. The
fibroblasts were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) GlutaMAX supplemented with 10% (v/v)
heat-inactivated fetal bovine serum and 1% (v/v) penicillin-
streptomycin, and they were maintained at 37°C, humidified
and 5% CO2 in air.
Quantification of CoQ10 levels
CoQ10 levels were quantified using a tandem mass spectrometer
with a 2975 HPLC (Waters, Manchester, UK) as previously
described.12 A hexane:ethanol (5:2, v/v) extraction was initially
performed and the upper hexane layer was retained for analysis.
Samples were resuspended in 50:50 HPLC grade ethanol and
methanol. Separation was achieved using a 3 μM Hypersil Gold
C4 (150 mm×3 mm, 3 mm) with a Gold C4 guard column (3,
10 mm length, 3 mm) operated at 40°C at a flow rate of 0.4 mL/
min. The mobile phases consisted of methanol, 4 mM ammo-
nium acetate 0.1% formic acid and methanol:isopropanol:formic
acid (45:55:0.5, v/v/v) containing 5 mM methylamine as an ion
pair reagent. Isocratic delivery of the mobile phase ensured
elution of the CoQ10 methylammonium adduct at approximately
8 min. D6-CoQ10 was used as an internal standard.
MRC enzyme activities
Activities of MRC complex I, complex II–III, complex IV (cyto-
chrome c oxidase) and citrate synthase (CS) were determined in
the fibroblast cells according to methods previously described.13
Results were expressed as a ratio to CS activity and were nor-
malised against protein. Protein quantification was determined
using the Lowry method using bovine serum albumin as a
standard.14
RESULTS
Clinical features
This 35-year-old lady started to experience myoclonus and jerky
tremor in the head and limbs at 10 years old. Slurred speech
and unsteady gait developed subsequently in her second decade.
There was no response to levodopa. By 30 years of age, she had
become wheelchair-dependent because of the ataxic myoclonic
gait. She also had difficulty in writing and holding objects due
to ataxia and involuntary movements. Her speech fatigued
easily, was often tremulous and dysarthric and she also com-
plained of muscle fatigue on exertion. One of the four siblings,
currently 32 years old, had a similar presentation with myoclo-
nus, tremor and unsteady gait with the onset at age 14 years.
Their parents are first cousins from Pakistan (pedigree shown in
figure 1B).
Examination when 35 years old showed cerebellar dysarthria
with a tremulous quality to her speech. Eye movements were
full with jerky pursuit, marked course tremor of the hands and
head, which was both jerky and dystonic in nature. There was
upper limb myoclonus, and both upper and lower limb move-
ments were uncoordinated when performing the finger nose
task and the heel-knee-shin test. Her gait was ataxic and inter-
rupted by frequent myoclonic jerks and she was unable to
tandem walk. Her cognition and visual acuity were normal. She
had symmetrical normal reflexes, flexor plantars, normal
sensory examination and full muscle power. Her affected
brother also had myoclonic movements, ataxic gait and dysarth-
ric speech when examined at age 32 years.
Brain MRI when 35 years old showed mild cerebellar atrophy
which was consistent with previous reports of patients with
ADCK3 mutations. Nerve conduction studies and needle elec-
tromyography were normal. It is interesting to note the rela-
tively mild phenotype even after 20 years of progressive
symptoms. In both affected siblings, acquired causes of ataxia
were excluded as was Friedreich’s ataxia, ataxia with oculo-
motor apraxia type 1 (AOA1), ataxia with oculomotor apraxia
type 2 (AOA2), ataxia telangiectasia, early onset primary dys-
tonia (DYT1), Vitamin E deficiency, Wilson’s disease and spino-
cerebellar ataxia type 1–3.
WES and variant validation
The process of variant prioritisation is summarised in figure 1A.
A total of 17 240 exonic variants were identified in the index
patient. According to the Consensus Coding Sequences hg19
definition of the exome, 92% of exome capture baits had at
least 10× depth, and 85% at least 30× depth. After excluding
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synonymous variants and those with MAF >1%, 78 coding
variants remained. These were screened against genes known
to be associated with autosomal-recessive cerebellar ataxias
and related neurological disorders. A homozygous 1 bp inser-
tion in the ADCK3 (NM_020247; c.1844_1845insG; p.
Ser616Leufs*114) was identified (figure 1C). The variant was
validated by Sanger sequencing. Genetic analysis of the affected
brother documented the segregation of this variant within the
family (figure 1D).
The genomic structure of the human ADCK3 gene and muta-
tions in this gene are illustrated in figure 2A. These mutations
were classified by the patient’s age of onset. Our family is the
second kindred of ADCK3 mutation with a juvenile onset of
disease (between 10 and 20 years), with a single previous study
reporting a family with compound heterozygous missense muta-
tions in ADCK3: R271C and A304T.9
The novel frameshift we have identified is localised to the
C-terminal of ADCK3, and results in an alteration of several
highly conserved codons in the last coding exon. Furthermore,
the frameshift is predicted to eliminate the original stop codon
and allow translation to continue on into the three prime
untranslated regions (30UTR), extending the peptide by 81
amino acids (figure 2B).
CoQ10 level and MRC enzyme activity
The serum CoQ10 level of the patient was found to be within
the normal range, however, CoQ10 level in the patient’s
fibroblast was low—35% of the average CoQ10 level of con-
trols. The assay of MRC enzymes in fibroblasts also revealed
that the activities of complex I and complexes II–III were signifi-
cantly reduced as compared with controls. A decrease in activ-
ities of complexes II–III is compatible with CoQ10 deficiency, as
the activity of this linked enzyme system is dependent upon
endogenous CoQ10.15
Details of these analyses are shown in table 1.
Treatment and outcome
Following the identification of primary CoQ10 deficiency in the
index patient, CoQ10 replacement was initiated with a starting
dose of 200 mg twice per day. After 3 months of therapy, her
myoclonic symptoms had dramatically improved whereby she
was able to discontinue clonazepam which she had been taking
for the previous 2 years to manage her frequent myoclonic
jerking. The quality of her speech also improved and was less
tremulous although there remained some residual dysarthria.
Self-reported symptoms of fatigue had also improved.
These improvements were sustained when she was reviewed
6 months after initiation of CoQ10 replacement. There was sub-
jective and objective improvement in her ataxia with a reduction
in SARA (scale for the assessment and rating of ataxia, see
online supplementary data) scores dropped from 17 to 13
(table 2). Her affected sibling has also shown improvement in
speech and fatgue on taking CoQ10 100 mg twice daily for
3 months. The proband and affected brother will be assessed
Figure 1 Genetic study and pedigree of the autosomal-recessive cerebellar ataxias (ARCA) family with ADCK3 S616Lfs mutation. (A) Filtering and
prioritisation of variants from whole exome sequencing in the index patient. The criteria of filters were described in the text. (B) Pedigree of this
family. The index patient is labelled with a black star. Based on the consanguinity, only homozygous variants were selected. (C) A good sequence
depth up to 122× and the homozygosity of the novel ADCK3 mutation as the insertion G was detected in 110 of the total 122 counts were shown
when inspected with the Integrative Genomics Viewer (IGV). (D) Sanger sequencing validated the mutation and proved its segregation with the
affected brother.
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further at 9 and 6 months, respectively, to see if improvement is
sustained.
DISCUSSION
We demonstrate genetic and biochemical data in a family with a
novel frameshift mutation in the ADCK3 gene and with the
phenotype of a complex ataxia-myoclonus syndrome, CoQ10
deficiency and abnormal MRC enzyme activities. One of the
unusual features of this family is an onset in the second decade,
which is later than most previously reported cases with ADCK3
mutations. Also, this family was affected with marked myoclonic-
dystonic movements but relatively mild cerebellar ataxia, suggest-
ing a wide phenotypic spectrum of ADCK3 mutations.
To date, autosomal recessive mutations in ADCK3 have only
been identified in 22 patients from 13 families, and these muta-
tions have been associated with clinically heterogeneous dis-
eases.9 Patients usually present with a complex neurological
phenotype, with cerebellar ataxia as the predominant manifest-
ation.8–11 In this family, cerebellar symptoms were relatively
mild compared to the disabling myoclonus and involuntary
movements which affected both siblings. This report shows that
ADCK3 mutations should be considered a potential cause of
unexplained complex neurological syndromes even when cere-
bellar ataxia is not the predominant feature.
Unlike previous reports in which the majority of patients had
the onset in their childhood or infancy (figure 2),8–11 we report
the second kindred with a juvenile onset and provide further
evidence that ADCK3 mutations can cause with a variable age at
onset.
In our patient, the diagnosis of CoQ10 deficiency was con-
firmed biochemically by measurement in fibroblasts. Significantly
reduced activities of MRC enzymes were also observed in fibro-
blasts. CoQ10 measurement in muscle is the gold standard for
diagnosis of CoQ10 deficiency as plasma concentrations of
Figure 2 Genomic location of ADCK3 S616Lfs mutation and the mutant peptide sequence. (A) Genomic structure of the human ADCK3 gene is
shown. All ADCK3 mutations reported in literature to date are shown in the gene and grouped by the average of patient’s age of onset in each
family. The novel mutation identified in this study is marked with a black star. #R271C and A304T are two compound heterozygous mutations
detected within a previously reported family. D420Wfs, Q167Lfs,Y514C, T584del, L314_Q369del and G549S were reported in Lagier-Tourenne
2008.8 E551K, R213W, G272V, G272D and N465Dfs were reported in Mollet 2008.11 R348X, R348X and L379X were reported in Gerald 2010.10
R271C, A304T, A304V, R299W and Y429C were reported in Horvath 2012.9 (B) Multiple species alignment shows this frameshift mutation changes
several highly conserved amino acid codons in the terminal segment of ADCK3 and eliminates the original stop codon, thus extending the peptide
by 81 amino acids.
Table 1 CoQ10 levels and the mitochondrial respiratory chain enzyme activies in the patient with ADCK3 S616Lfs mutation
Patient Control P/C ratio p Value
CoQ 10 levels (pmol/mg)
In serum 43.00 37–133* /
In fibroblasts 31.29 89.3† (n=50) 35.0% <0.05
MRC enzyme activity
CI/CS 0.15±0.167 0.82±0.18 (n=3) 18.3% <0.05
CII+CIII/CS 0.046±0.03 0.122±0.02 (n=3) 37.7% <0.05
CIV/S 0.017±0.0052 0.015±0.004 (n=3) 113.3% ns
Abnormal values are shown in bold. When experiments were carried out more than once, values are given as means±SE of the mean.
*From the diagnostic laboratory at National Hospital of Neurology and Neurosurgery, Queen Square, London, UK.
†Reference range 57.0–121.6 pmol/mg, average 89.3 pmol/mg; Age: 20.75±1.4 years (range, 0.03–55 years); ratio of males to females, 2:3.12
CI, complex I (NADH ubiquinone oxidoreductase); CII, complex II (succinate ubiquinone oxidoreductase); CIII, complex III (ubiquinol cytochrome c oxidoreductase); CIV, complex IV
(cytochrome c oxidase: EC 1.9.3.1); CS, citrate synthase; MRC enzyme activity, the mitochondrial respiratory chain enzyme activities assessed in patient’s fibroblasts; P/C ratio, the ratio
of patient’s measurement to control value.
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CoQ10 are not reliable and may be influenced by dietary
factors.12 However, the measurement in muscle may be normal
particularly when the deficiency is mild.4 Assessing CoQ10 levels
in fibroblasts has been documented to be a reliable method to
diagnose CoQ10 deficiency.12 13 15 16 Our results confirm that
measuring CoQ10 levels in fibroblasts can be an alternative to
muscle measurement.
CoQ10 replacement therapy resulted in subjective and object-
ive improvement in patient symptoms and function. The most
marked improvements were in reduction of myoclonus and
speech improvements although there were also improvements in
ataxic symptoms as measured by the SARA scale. CoQ10 defi-
ciency is one of the few treatable causes of ataxia, and symptom
improvement following replacement has been observed in a
number of patients, although treatment protocols are yet to be
standardised.5 17 There are few long-term studies, however, and
it is not clear for how long these benefits might be sustained, or
whether they alter the overall disease course.
The number of patients reported to carry ADCK3 mutations
is still low. This is partly due to the non-specific genotype-
phenotype correlations of CoQ10-associated genes and the diffi-
culty in screening all potential genes in suspicious cases. CoQ10
deficiency is associated with clinically heterogeneous diseases,
including cerebellar ataxia, encephalomyopathy, severe infantile
multisystemic disease, nephropathy, myopathy and multiple-
system atrophy, and the number of genes involved in the biosyn-
thetic pathway for CoQ10 is increasing.4 18 Our study showed
that WES is a powerful tool to detect mutations in rare known
genes, particularly in unexplained complex syndromes with high
genetic heterogeneity. With the application of WES and other
NGS technology, more patients with CoQ10 deficiency are
likely to be identified and additional studies may lead to more
effective therapies.
The novel mutation identified in this study also provides new
insights into the pathogenesis of ADCK3 mutations. This is the
first ADCK3 mutation which results in the loss of the stop
codon and translation into the UTR. CoQ10 deficiency and
reduced respiratory enzymes activities in the patient’s fibroblast
confirmed the pathogenicity of this mutation. It is not yet clear
through what mechanism the function of the protein is impaired
by the extended C-terminal sequence. The elongated mutant
protein may bear less structure stability and thus be incompetent
to carry out its function in mitochondria and CoQ10 biosyn-
thesis. However, given the relatively mild disease course, it is
likely that some residual function remains.
In summary, our study extends the phenotypic spectrum of
ADCK3 mutations associated with ARCA. Mutations are not
only restricted to childhood-onset ataxias, and other neuro-
logical features, such as myoclonus, may be prominent. This
study also increases the understanding of genetic and functional
effects of ADCK3 mutations. The loss of a stop codon mutation
identified in this gene suggests that the terminal segment of
ADCK3 may play an unknown but essential role in its normal
function. The great response to treatment in our patient high-
lights the importance of identifying a potentially treatable cause,
CoQ10 deficiency, in unexplained recessive cerebellar ataxia, or
ataxia-associated complex syndromes.
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